Pharmaceuticals

Merck

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Allworth Financial LP Increases Merck Holdings by 71.4%

Amundi Increases Stake in Merck Above 3% Threshold

Merck Shows Latest Progress in Its Oncology Portfolio

Merck Unaffected by Daiichi Sankyo's Updated Antibody-Drug Conjugate Supply Plan

World Investment Advisors Increased Holdings in Merck in Q4

Merck completes acquisition of Terns Pharmaceuticals, Inc.

Merck Reports Q1 2026 Earnings, Revenues Beat Estimates

Merck Reports 5% Revenue Growth in Q1 2026 and Raises Full-Year Guidance

Merck Reports Strong Q1 Earnings, Keytruda Sales Surge

Merck released FY2026 Q1 earnings on April 30 Pre-Market (EST), actual revenue USD 16.29 B (forecast USD 15.85 B), actual EPS USD -1.72 (forecast USD -1.5834)

Merck Starts Phase III ELOWEN Project to Treat Lupus Patients

Merck Reports Q1 Keytruda Revenue of 8.034 Billion USD

Merck Reports Quarterly Loss Due to Acquisition Charges

Merck & Co. Announces Creation of a Separate Oncology Business Unit

Merck to Report Q1 Earnings, Market Expectations Diverge

Merck Successfully Acquires Terns Pharmaceuticals

Merck to Release FY2026 Q1 Earnings on April 30 Pre-Market EST, Forecast Revenue USD 15.84 B, EPS USD -1.5834

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Merck Group (MRK.US) Q1 2026 Earnings Conference Call

Merck & Co., Inc. (MRK.US) Q4 2025 Earnings Conference Call

Merck & Co., Inc. (MRK.US) Q3 2025 Earnings Conference Call

Merck Group (MRK.US) Q2 2025 Earnings Conference Call

Merck & Co., Inc. (MRK.US) Q1 2025 Earnings Conference Call

Merck & Co., Inc. (MRK.US) Q4 2024 Earnings Conference Call

Merck & Co. (MRK.US) 2024 Third Quarter Earnings Conference Call

Merck has launched a Hypertension Risk Checker to raise awareness about elevated resting heart rates as a potential cardiovascular risk, coinciding with World Hypertension Day. The initiative aims to encourage proactive heart health management, addressing the fact that 1.4 billion people globally live with high blood pressure, many unaware of their condition. Merck emphasizes the importance of early detection and education in managing heart health, marking four decades of commitment to cardiovascular care in the Gulf region.

Zawya

Merck KGaA

ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker

SBIO

LABU

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

NOVARTIS AG

Johnson & Johnson

Bristol Myers Squibb

AstraZeneca

ProShares Ultra Health Care ETF

Direxion Pharma & Medical Bull 3X

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

iShares US Pharma

AstraZeneca PLC

Bristol-Myers Squibb Company

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

ARKG

IBBQ

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer | MRK Stock News

StockTitan

iShares Global Healthcare

SPDR S&P Biotech

VanEck Biotech ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer | MRK Stock News

Merck & Co. Inc. (MRK) shares fell 1.79% to $111.38 on Friday, marking its second consecutive day of losses. The stock is 11.00% below its 52-week high of $125.14. In comparison, competitors like Johnson & Johnson, Pfizer, and Eli Lilly also experienced declines, but Merck underperformed relative to them. The trading volume was 9.8 million, slightly above its 50-day average of 9.5 million.

Merck(MRK.US)

ZAWYA: Merck marks World Hypertension Day with launch of Hypertension Risk Checker

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan (Sac-TMT) Met Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer | MRK Stock News

Merck & Co. Inc. Stock Underperforms Friday When Compared To Competitors